-
公开(公告)号：EP3328994A1
公开(公告)日：2018-06-06
申请号：EP16833684.0
申请日：2016-08-01
申请人： Memorial Sloan-Kettering Cancer Center , The United States of America, as represented by The Secretary, Department of Health and Human Services
IPC分类号： C12N5/0783 , C07K14/725 , C07K16/30
CPC分类号： C07K16/2803 , A61K35/17 , A61K2039/505 , A61P35/00 , C07K14/7051 , C07K14/70521 , C07K16/3061 , C07K2317/21 , C07K2317/24 , C07K2317/30 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/92 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/70
摘要： The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., multiple myeloma). It relates to anti-CD56 antibodies, chimeric antigen receptors (CARs) that specifically target human CD56, and immunoresponsive cells comprising such CARs. The presently disclosed CD56-specific CARs have enhanced immune-activating properties, including anti-tumor activity.
-
2.发明公开MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF 审中-公开GEGEN MESOTHELIN GERICHETECHIMÄREANTIGENREZEPTOREN UND VERWENDUNGEN DAVON
公开(公告)号：EP3151854A2
公开(公告)日：2017-04-12
申请号：EP15803100.5
申请日：2015-06-05
申请人： Memorial Sloan Kettering Cancer Center , The United States of America, as represented by The Secretary, Department of Health and Human Services
IPC分类号： A61K39/00
CPC分类号： C07K16/28 , A61K35/00 , A61K38/00 , A61K2039/505 , C07K14/4748 , C07K14/705 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K16/30 , C07K2317/21 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2319/02 , C07K2319/03
摘要： The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) that specifically target human mesothelin, and immunoresponsive cells comprising such CARs. The presently disclosed mesothelin-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.
摘要翻译： 目前公开的主题提供了用于增强针对癌症和病原体的免疫应答的方法和组合物。 它涉及特异性靶向人间皮素的嵌合抗原受体（CAR）和包含这种CAR的免疫反应性细胞。 目前公开的间皮素靶向CAR具有增强的免疫活化性质，包括抗肿瘤活性。
-
公开(公告)号：EP3685842A1
公开(公告)日：2020-07-29
申请号：EP20158336.6
申请日：2015-06-05
申请人： Memorial Sloan-Kettering Cancer Center , The United States of America, as represented by The Secretary, Department of Health and Human Services
IPC分类号： A61K35/00 , A61K38/00 , A61K39/00 , C07K14/47 , C07K14/705 , C07K14/725 , C07K16/28 , C07K16/30 , A61P1/18 , A61P29/00 , A61P31/00 , A61P35/00 , A61P37/04 , A61P37/06 , A61P43/00
摘要： The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) that specifically target human mesothelin, and immunoresponsive cells comprising such CARs. The presently disclosed mesothelin-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.
-
公开(公告)号：EP3151854B1
公开(公告)日：2020-02-26
申请号：EP15803100.5
申请日：2015-06-05
申请人： Memorial Sloan Kettering Cancer Center , The United States of America, as represented by The Secretary, Department of Health and Human Services
IPC分类号： A61K35/00 , A61K38/00 , A61K39/00 , C07K14/47 , C07K14/705 , C07K14/725 , C07K16/28 , C07K16/30
-
公开(公告)号：EP4166148A1
公开(公告)日：2023-04-19
申请号：EP22186683.3
申请日：2015-06-05
申请人： Memorial Sloan-Kettering Cancer Center , The United States of America, as represented by The Secretary, Department of Health and Human Services
IPC分类号： A61K35/00 , A61K38/00 , A61K39/00 , C07K14/47 , C07K14/705 , C07K14/725 , C07K16/28 , C07K16/30 , A61P1/18 , A61P29/00 , A61P31/00 , A61P35/00 , A61P37/04 , A61P37/06 , A61P43/00
摘要： The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) that specifically target human mesothelin, and immunoresponsive cells comprising such CARs. The presently disclosed mesothelin-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.
To be accompanied, when published, by Figure 1 of the drawings.-
公开(公告)号：EP4138865A2
公开(公告)日：2023-03-01
申请号：EP21793613.7
申请日：2021-04-26
申请人： Memorial Sloan Kettering Cancer Center , Millennium Pharmaceuticals, Inc. , Sloan-Kettering Institute for Cancer Research , Memorial Hospital for Cancer and Allied Diseases
发明人： FEUCHT, Judith , MANSILLA-SOTO, Jorge , RIVIERE, Isabelle , SADELAIN, Michel , VINCENT, Loic , SHAPIRO, Gary , NG, Mei Rosa , TAVARES, Dan , HE, Xingyue
IPC分类号： A61K35/17 , A61K39/395 , C07K14/705
-
公开(公告)号：EP2981607B1
公开(公告)日：2020-08-19
申请号：EP14722926.4
申请日：2014-04-03
IPC分类号： C12N5/0783 , C12N5/074
-
公开(公告)号：EP3463401A1
公开(公告)日：2019-04-10
申请号：EP17807666.7
申请日：2017-06-05
发明人： PARK, Jae, H. , RIVIERE, Isabelle , WANG, Xiuyan , PURDON, Terence , SADELAIN, Michel , BRENTJENS, Renier, J.
IPC分类号： A61K35/17 , A61K38/17 , C12N5/0783
-
9.发明授权METHOD AND COMPOSITION TO INCREASE RADIATION-INDUCED TUMOR THERAPEUTIC EFFECTS 有权增加辐射诱发的肿瘤治疗效果的方法和组合物
公开(公告)号：EP2510091B1
公开(公告)日：2017-06-28
申请号：EP10801023.2
申请日：2010-12-07
发明人： KOLESNICK, Richard, N. , STANCEVIC, Branka , SADELAIN, Michel , FUKS, Zvi , VARDA-BLOOM, Nira , HARATS, Dror
IPC分类号： C12N9/16 , C12N15/861 , A61K48/00 , A61K38/00
CPC分类号： A61K48/005 , A61K35/761 , A61K38/00 , A61K45/06 , A61N2005/1098 , C12N9/16 , C12N15/86 , C12N2710/10332 , C12N2710/10343 , C12N2830/002 , C12N2830/008 , C12N2830/15 , C12N2830/85
摘要： Disclosed herein are methods and compositions for treating cancer by increasing radiation-induced damage to cancer without increasing radiation-induced side effects by increasing secretory ASMase levels specifically in tumor endothelium, and inducing apoptosis of tumor endothelial cells by treating the tumor with radiation. ASMase levels are increased in tumor endothelium by administration of a recombinant DNA construct comprising a region coding for a functional ASMase linked to particular transcriptional regulatory sequences that confer tissue-specific expression of ASMase.
摘要翻译： 本文公开了通过增加辐射诱导的癌症损伤而不增加辐射诱导的副作用，通过特异性地增加肿瘤内皮中的分泌性ASMase水平，和通过用放射线治疗肿瘤诱导肿瘤内皮细胞凋亡来治疗癌症的方法和组合物。 通过施用包含编码与赋予ASMase的组织特异性表达的特定转录调控序列连接的功能性ASMase的区域的重组DNA构建体，肿瘤内皮中的ASMase水平增加。
-
10.发明公开EFFECTIVE GENERATION OF TUMOR-TARGETED T-CELLS DERIVED FROM PLURIPOTENT STEM CELLS 审中-公开WIRKSAME ERZEUGUNG VON TUMORGERICHTETEN T-ZELLEN AUS PLURPOTENTEN STAMMZELLEN
公开(公告)号：EP2981607A2
公开(公告)日：2016-02-10
申请号：EP14722926.4
申请日：2014-04-03
IPC分类号： C12N5/0783 , C12N5/074
摘要： The present invention relates to the field of adoptive immunotherapy. The invention provides methods for generating phenotypically defined, functional, and/or expandable T cells from pluripotent stem cells engineered through safe genetic modifications. The engineered cells may provide one or more of: 1) targeting a specific predetermined antigen expressed on the cell surface of a target cell in an HLA independent manner, 2) enhanced survival and functional potential 3) “off-the-shelf” T cells for administration to multiple recipients, eventually across immunogenic barriers, and/or 4) cytotoxic potential and anti-tumor activity.
摘要翻译： 本发明涉及过继免疫治疗领域。 本发明提供从通过安全遗传修饰工程化的多能干细胞产生表型定义的功能性和/或可扩增T细胞的方法。 工程细胞可以提供以下一种或多种：1）以HLA独立的方式靶向在靶细胞的细胞表面上表达的特定预定抗原，2）增强的存活和功能潜力3）“现成”T细胞 用于给予多个受体，最终跨越免疫原性屏障，和/或4）细胞毒性潜力和抗肿瘤活性。
-
-
-
-
-
-
-
-
-
搜索结果
45 条记录 (耗时 0.034 秒)
